MX2016003757A - Sal de dihidrogenofosfato de disoproxilo de tenofovir. - Google Patents

Sal de dihidrogenofosfato de disoproxilo de tenofovir.

Info

Publication number
MX2016003757A
MX2016003757A MX2016003757A MX2016003757A MX2016003757A MX 2016003757 A MX2016003757 A MX 2016003757A MX 2016003757 A MX2016003757 A MX 2016003757A MX 2016003757 A MX2016003757 A MX 2016003757A MX 2016003757 A MX2016003757 A MX 2016003757A
Authority
MX
Mexico
Prior art keywords
tenofovir disoproxil
dihydrogenphosphate salt
dihydrogenphosphate
salt
cukî
Prior art date
Application number
MX2016003757A
Other languages
English (en)
Inventor
Jan Holan
Ludek Ridvan
Michal Zapadlo
Ondrej Dammer
Josef Beránek
Vladimir Kral
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of MX2016003757A publication Critical patent/MX2016003757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

La presente invención se refiere al dihidrogenofosfato de disoproxilo de Tenofovir, que muestra las siguientes reflexiones características en el XRPD medidas por la emisión de CuKa 5.6; 7.7; 12.4; 13.6; 16.4; 22.4 a 25.4 ± 0.2 * 2T, y métodos para la preparación del mismo.
MX2016003757A 2013-10-09 2014-09-22 Sal de dihidrogenofosfato de disoproxilo de tenofovir. MX2016003757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004844.0A EP2860184B1 (en) 2013-10-09 2013-10-09 Dihydrogenphosphate salt of Tenofovir disoproxil
PCT/EP2014/002562 WO2015051875A1 (en) 2013-10-09 2014-09-22 Dihydrogenphosphate salt of tenofovir disoproxil

Publications (1)

Publication Number Publication Date
MX2016003757A true MX2016003757A (es) 2016-07-08

Family

ID=49354420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003757A MX2016003757A (es) 2013-10-09 2014-09-22 Sal de dihidrogenofosfato de disoproxilo de tenofovir.

Country Status (10)

Country Link
EP (1) EP2860184B1 (es)
JP (1) JP2016534047A (es)
KR (1) KR20160067843A (es)
CN (1) CN105612167A (es)
BR (1) BR112016007617A2 (es)
EA (1) EA201690622A1 (es)
IL (1) IL244848A0 (es)
MX (1) MX2016003757A (es)
PT (1) PT2860184T (es)
WO (1) WO2015051875A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160003532A (ko) * 2014-07-01 2016-01-11 한미약품 주식회사 테노포비어 디소프록실 인산염과, 비금속염 붕해제 및 비금속염 활택제를 포함하는 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4033494B2 (ja) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
NZ333687A (en) 1996-07-26 2000-08-25 Gilead Sciences Inc Phosphonomethoxy nucleotide analogs
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
JP4173202B2 (ja) 1997-07-25 2008-10-29 ギリアード サイエンシーズ，インコーポレイテッド ヌクレオチドアナログ組成物および合成方法
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
ES2532502T3 (es) 2006-07-12 2015-03-27 Mylan Laboratories Limited Proceso para la preparación de tenofovir
WO2008140302A1 (en) 2007-05-14 2008-11-20 Ultimorphix Technologies B.V. Polymorphic forms of tenofovir disoproxil fumarate
JP2010527996A (ja) 2007-05-22 2010-08-19 ウルティモルフィクス・テクノロジーズ・ベー・フェー テノホビルジソプロキシル−ヘミフマル酸共結晶
WO2009064174A1 (en) 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use
AU2008334924A1 (en) * 2007-12-12 2009-06-18 Ultimorphix Technolgies B.V. Solid forms of Tenofovir disoproxil
AU2008355336B2 (en) * 2008-04-25 2014-04-10 Cipla Limited Crystalline form of tenofovir disoproxil and a process for its preparation
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
CN101781334B (zh) * 2010-03-04 2012-11-28 福建广生堂药业股份有限公司 替诺福韦酯的盐化合物，其制备方法和药物应用
WO2012137227A2 (en) * 2011-04-08 2012-10-11 Laurus Labs Private Limited Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
WO2013132314A1 (en) * 2012-03-05 2013-09-12 Laurus Labs Private Limited Tenofovir phosphate, processes for the preparation and pharmaceutical composition thereof

Also Published As

Publication number Publication date
EP2860184B1 (en) 2018-08-29
EP2860184A1 (en) 2015-04-15
CN105612167A (zh) 2016-05-25
EA201690622A1 (ru) 2016-08-31
JP2016534047A (ja) 2016-11-04
BR112016007617A2 (pt) 2017-08-01
KR20160067843A (ko) 2016-06-14
PT2860184T (pt) 2018-11-20
IL244848A0 (en) 2016-05-31
WO2015051875A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2015012743A (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
MY167953A (en) Flavoured rods for use in aerosol-generating articles
MX2016006200A (es) Metodos para preparar inhibidores de la replicacion de virus de influenza.
MX2016004945A (es) Procesos para la preparacion de compuestos plaguicidas.
ZA201508278B (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
PT3079476T (pt) Complexos de cobre-zinco-amónio solubilizados em ácido, composições, preparações, métodos e utilizações
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
EP3060126A4 (en) Systems and methods for generating respiration alarms
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
IN2013MU03862A (es)
MX369506B (es) Composiciones de sales metálicas.
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
IN2013MU01111A (es)
HK1220627A1 (zh) 氯苯那敏或其鹽的穩定化方法
MX2016003757A (es) Sal de dihidrogenofosfato de disoproxilo de tenofovir.
PT2980096T (pt) Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
EP3089734A4 (en) Antiperspirants with limited coating agents and methods for producing the same
EP2980093A4 (en) Bis(6-methyl-3-sulphophenyl)(2-methylphenyl)phosphine, ammonium salt thereof, and method for producing same
MX345278B (es) Procedimiento de sintesis del 3,4-dimetoxibiciclo[4.2.0]octa-1,3,5 -trien-7-carbonitrilo, y aplicacion a la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
TWD159828S (zh) 連接器
PL3347309T3 (pl) Sposoby wytwarzania soli srebra(ii) i ich hydratów, produkty otrzymane tymi sposobami i ich zastosowanie do modyfikacji struktury cząsteczek związków organicznych